Scienza e Tecnologia
DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA
Trelstar (Triptorelin) is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of Triptorelin Pamoate. First registered in
France in 1986, Triptorelin is currently marketed in more than 80 countries by Debiopharm's selected partners and is market leader in many territories worldwide.
Headquartered in Durban, South Africa ,
Aspen is a partner of choice as it is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets.
Aspen improves the health of patients in more than 150 countries through its high quality and affordable medicines. Active at every stage of the value chain,
Aspen is uniquely diversified by geography, product and manufacturing capability. The Group's key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands. For more information, please visit https://www.aspenpharma.com/.
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
Visit us www.debiopharm.com/
Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Dawn Bonine – Head of Communications
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
1. Globocan 2020; https://gco.iarc.fr/today/data/factsheets/populations/913-southern-africa-fact-sheets.pdf
2. https://mensfoundation.co.za/mens-health/prostate-cancer/